Skip to main content
main-content

ACR Convergence 2021 highlights

3–9 November
ACR Convergence 2021

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

Question mark illustration

The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with RA at high CV risk, show the ORAL Surveillance results.

ACR Convergence 2021

Olokizumab benefits extend to patients with RA refractory to methotrexate or TNF inhibitors

Inflamed joint pain (illustrative with model)

Olokizumab shows clinical and physical benefits for patients with rheumatoid arthritis (RA) with inadequate responses to methotrexate and tumor necrosis inhibitor (TNF) inhibitor therapy in the latest CREDO findings. Read now

ACR Convergence 2021

Add-on treatment for lupus nephritis: Should belimumab or voclosporin be used first?

The Great Debate

In “The Great Debate”, experts discussed which new add-on treatment option should be used first for patients with active lupus nephritis despite conventional therapy. Read now

Expert video interviews from ACR Convergence 2021

12-11-2021 | ACR 2021 | Conference coverage | Video

Olokizumab: What makes it an effective and novel treatment for RA?

Roy Fleischmann discusses the implications of the CREDO2 and 3 trial findings looking at olokizumab efficacy versus adalimumab as an add-on to methotrexate and in TNF inhibitor non-responders.

07-11-2021 | ACR 2021 | Conference coverage | Video

Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?

Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis.

06-11-2021 | ACR 2021 | Conference coverage | Video

The ARIAA trial of abatacept for subclinical arthritis

Jürgen Rech outlines the findings from the ARIAA trial, which demonstrated benefits of abatacept in people at risk for rheumatoid arthritis, and discusses the potential role of treating subclinical inflammation to delay or prevent the onset of clinical disease.

Tofacitinib safety

Treatments for systemic lupus erythematosus, lupus nephritis

Treat-to-target strategies in gout

Early rheumatoid arthritis studies

06-11-2021 | ACR 2021 | Conference coverage | News

Abatacept shows potential for subclinical arthritis

06-11-2021 | ACR 2021 | Conference coverage | News

Targeting unmet needs could improve QoL in early RA

09-11-2021 | ACR 2021 | Conference coverage | News

Piclidenoson misses primary endpoint for early RA

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

More news from ACR Convergence 2021

10-11-2021 | ACR 2021 | Conference coverage | News

High BMI may adversely affect PsA treatment response

09-11-2021 | ACR 2021 | Conference coverage | News

No benefit to methotrexate use with ustekinumab in PsA

09-11-2021 | ACR 2021 | Conference coverage | News

Pirfenidone shows promise for patients with RA-ILD

07-11-2021 | ACR 2021 | Conference coverage | News

Brepocitinib shows promise in psoriatic arthritis

07-11-2021 | ACR 2021 | Conference coverage | News

Belimumab, arimoclomol disappoint in myositis trials


This information is brought to you by Medicine Matters in partnership with medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology.


Image Credits